Milestone Pharmaceuticals (NASDAQ:MIST) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Milestone Pharmaceuticals from “strong sell” to “sell,” while broader analyst consensus remains “Moderate Buy,” with a $6.40 average price target.
• For the latest quarter, Milestone reported a loss of $0.18 per share, narrower than the $0.22 loss analysts expected, and revenue of $2.96 million versus a $1.00 million estimate.
• CARDAMYST revenue rose 73% from the prior quarter to about $1 million. The company plans to cut operating expenses by roughly 30% and says its $145.4 million in cash and investments should fund operations into late 2028.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a report issued on Saturday, Wall Street Zen reports.

A number of other equities research analysts have also recently commented on MIST. HC Wainwright reiterated a "buy" rating on shares of Milestone Pharmaceuticals in a research report on Thursday, September 3rd. Cantor Fitzgerald initiated coverage on Milestone Pharmaceuticals in a research report on Thursday, August 20th. They set an "overweight" rating and a $3.00 price objective on the stock. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Milestone Pharmaceuticals in a report on Monday, October 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $6.40.

Milestone Pharmaceuticals Stock Performance

MIST opened at $0.52 on Friday. The company has a quick ratio of 7.92, a current ratio of 8.13 and a debt-to-equity ratio of 3.25. The company has a market cap of $64.74 million, a price-to-earnings ratio of -0.75 and a beta of 1.07. Milestone Pharmaceuticals has a 52-week low of $0.50 and a 52-week high of $3.06. The firm's fifty day simple moving average is $0.80 and its two-hundred day simple moving average is $1.31.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last released its quarterly earnings results on Friday, November 13th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.04. The company had revenue of $2.96 million for the quarter, compared to analyst estimates of $1.00 million. Equities analysts anticipate that Milestone Pharmaceuticals will post -0.84 earnings per share for the current fiscal year.

Institutional Trading of Milestone Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. RVW Wealth LLC acquired a new position in shares of Milestone Pharmaceuticals in the 3rd quarter worth approximately $994,000. Seven Fleet Capital Management LP purchased a new stake in Milestone Pharmaceuticals in the first quarter valued at approximately $397,000. TRU Independence Asset Management 2 LLC acquired a new position in Milestone Pharmaceuticals during the second quarter worth $201,000. Renaissance Technologies LLC acquired a new position in Milestone Pharmaceuticals during the first quarter worth $154,000. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Milestone Pharmaceuticals during the second quarter worth $134,000. 86.18% of the stock is owned by institutional investors and hedge funds.

Latest Milestone Pharmaceuticals News

These are some of the MIST news items that stood out recently:

• Positive Sentiment: MIST reported a third-quarter loss of $0.18 per share, narrower than analysts’ expected $0.22 loss, and revenue of $2.96 million versus the $1.00 million consensus estimate. Zacks Q3 results
• Positive Sentiment: CARDAMYST product revenue reached about $1.0 million, up 73% from the prior quarter, with roughly 3,400 prescriptions and coverage across about two-thirds of commercially insured lives. CARDAMYST and runway update
• Positive Sentiment: The company plans to cut operating expenses by about 30%, while keeping its sales team and AFib-RVR Phase 3 program in place. It expects $145.4 million in cash and investments to fund operations into late 2028, beyond the trial’s anticipated second-half 2028 data readout. Company results and cost-efficiency measures

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cardiovascular conditions. Its work centers on therapies intended to give patients and caregivers options for managing acute heart rhythm episodes outside of a clinical setting. The company's lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. It is designed for self-administration to treat episodes of paroxysmal supraventricular tachycardia, a condition involving sudden episodes of abnormally fast heart rate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.